AR and adenocarcinoma: Notably, in the SU2C/PCF and Beltran 2016 cohorts, which include castration-resistant tumors that are pathologically characterized as adenocarcinoma with or without neuroendocrine features, several cases with a high level of NE signaling and negative AR signaling had developed a neuroendocrine feature in pathological morphology, which represent a more neuroendocrine-differentiated state.